Korzeniewska Marzena, Kołomecki Krzysztof, Stepień Henryk, Naze Maciej, Stepień Tomasz, Kuzdak Krzysztof
Department of General and Endocrinological Surgery, Medical University, Lódź.
Endokrynol Pol. 2005 Jan-Feb;56(1):39-44.
The growth and persistence of solid tumors and their metastases is connected with angiogenesis. This process is determined by activity of pro- and antyangiogenic factors. VEGF is the one of the most important factors having a stimulant effect on angiogenesis. Soluble forms of VEGF receptors are inhibitors of angiogenesis. The soluble forms of VEGF receptors containing extra cellular part of receptor, which binds ligand, seem to be real inhibitors of VEGF.
Evaluation the value of serum VEGF and soluble forms of VEGF receptors concentration as a marker of malignancy in patients with hormonal inactive adrenal tumors.
Twenty seven patients (18 female, 9 male; mean age 48+/-4.3 years) with adrenocortical carcinoma (N=8), adrenal metastases (N=4) and adrenocortical adenoma (N=15) were included in this study. Age- and gender-matched control samples were acquired from healthy volunteers (N=10). Serum VEGF and sVEGFR levels were determinated by means of ELISA assay. Statistical analysis was performed using the Student-t test, the Pearson's test and the series test.
In healthy controls mean VEGF level was 197.2 pg/ml, sVEGFR-1 43.5 pg/ml and sVEGFR-2 8976.3 pg/ml. Patients with adrenocortical carcinoma had the levels of VEGF (1263.8 pg/ml) significantly higher and of sVEGFR-2 (5893.7 pg/ml) significantly lower in comparison to control group (p<0.05). On the other hand the mean VEGF (334.2 pg/ml) concentration in patients with benign adrenocortical adenoma wasn't significant different than in control group (p>0.05) but mean sVEGFR-1 (21.7 pg/ml) and sVEGFR-2 (7106.4 pg/ml) concentrations were significantly lower than in the control (p<0.05). In metastases group mean VEGF (485.9 pg/ml) level was higher and sVEGFR-2 (5455.2 pg/ml) was lower than in control group (p<0.05).
These data suggest that determination of VEGF and sVEGFR concentration in the serum of patients with hormonal inactive adrenal tumors may be applied as an additional marker of malignancy.
实体瘤及其转移灶的生长和持续存在与血管生成有关。这一过程由促血管生成因子和抗血管生成因子的活性决定。血管内皮生长因子（VEGF）是对血管生成具有刺激作用的最重要因子之一。VEGF受体的可溶性形式是血管生成的抑制剂。含有与配体结合的受体细胞外部分的VEGF受体可溶性形式似乎是VEGF的真正抑制剂。
评估血清VEGF和VEGF受体可溶性形式的浓度作为激素非活性肾上腺肿瘤患者恶性肿瘤标志物的价值。
本研究纳入了27例患者（18例女性，9例男性；平均年龄48±4.3岁），其中肾上腺皮质癌8例，肾上腺转移瘤4例，肾上腺皮质腺瘤15例。从健康志愿者（10例）获取年龄和性别匹配的对照样本。采用酶联免疫吸附测定（ELISA）法测定血清VEGF和可溶性VEGF受体（sVEGFR）水平。使用学生t检验、皮尔逊检验和系列检验进行统计分析。
健康对照组中，VEGF平均水平为197.2 pg/ml，sVEGFR-1为43.5 pg/ml，sVEGFR-2为8976.3 pg/ml。与对照组相比，肾上腺皮质癌患者的VEGF水平（1263.8 pg/ml）显著更高，sVEGFR-2水平（5893.7 pg/ml）显著更低（p<0.05）。另一方面，良性肾上腺皮质腺瘤患者VEGF的平均浓度（334.2 pg/ml）与对照组相比无显著差异（p>0.05），但sVEGFR-1（21.7 pg/ml）和sVEGFR-2（7106.4 pg/ml）的平均浓度显著低于对照组（p<0.05）。转移瘤组的VEGF平均水平（485.9 pg/ml）高于对照组，sVEGFR-2（5455.2 pg/ml）低于对照组（p<0.05）。
这些数据表明，测定激素非活性肾上腺肿瘤患者血清中的VEGF和sVEGFR浓度可作为恶性肿瘤的一项附加标志物。
